Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit

• Main Authors: Praparattanapan,J., Tragoolpua,Y., Wongtrakul,J., Kotarathitithum,W., Chaiwarith,R., Nuntachit,N., Sirisanthana,T., Supparatpinyo,K.
• Format: Article
• Published: IOS Press 2015
• Subjects: Medicine (all); Biochemistry, Genetics and Molecular Biology (all)
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84871581278&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38233
• Institution: Chiang Mai University

Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug resistance occurs in a substantial number of patients. In resource-limited settings, genotypic resistance assay using a commercial kit is costly. Objective: Focus on the validation of an in-house HIV-1 specific genotypic drug resistance assay in Thai patients failing cART. Materials and methods: Results of HIV-1 genotypic drug resistance assay was evaluated by comparing an inhouse method to a commercial test. The TRUGENE HIV-1 genotyping kit was used in 79 plasma specimens (49 from HIV patients failing cART therapy and 30 from proficiency testing panels). Results: The results from the in-house assay were comparable to those obtained from the TRUGENE HIV-1 genotyping kit with >99.0% codon-to-codon agreement. The lower limit of detection by the in-house assay was approximately 100 copies/mL of HIV-1 RNA. In addition, this in-house assay would allow testing of samples from patients infected with HIV-1 subtype other than B. Conclusion: The in-house HIV-1 genotypic drug resistance assay may be used as an alternative to commercial kits, particularly in resource limited settings.